Please assess the completion status of the following clinical trial:

Trial Title: Initiating Transdermal Estradiol Therapy in Turner's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 60 subjects will be recruited from participating Pediatric Endocrinology Clinics in the United States.~* Subjects will be 11.5-13.0 years of age and must have completed at least 6 months of GH therapy prior to the study.~* Subjects may not have had any estrogen prior to the study. All subjects must be breast stage 1 and euthyroid prior to the study~* Those on thyroid medication will continue the appropriate thyroid replacement therapy during the study.~Exclusion Criteria:~* On estrogen therapy, breast stage 2 or greater, not on GH for at least 6 months.

- Gender: FEMALE
- Minimum Age: 138 Months
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- GH alone, Low dose E2 patch, Very Low-dose E2 patch (Type: EXPERIMENTAL): Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).